{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:17:39Z","timestamp":1779927459436,"version":"3.53.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T00:00:00Z","timestamp":1666224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Ophthalmol Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>To review the role of ocular surface epithelial (corneal and conjunctival) ion transporters in the pathogenesis and treatment of dry eye disease (DED).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>Currently, anti-inflammatory agents are the mainstay of DED treatment, though there are several agents in development that target ion transport proteins on the ocular surface, acting by pro-secretory or anti-absorptive mechanisms to increase the tear fluid film volume. Activation or inhibition of selected ion transporters can alter tear fluid osmolality, driving water transport onto the ocular surface via osmosis. Several ion transporters have been proposed as potential therapeutic targets for DED, including the cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCCs), and the epithelial sodium channel (ENaC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Ocular surface epithelial cell ion transporters are promising targets for pro-secretory and anti-absorptive therapies of DED.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40135-022-00295-3","type":"journal-article","created":{"date-parts":[[2022,10,20]],"date-time":"2022-10-20T08:05:17Z","timestamp":1666253117000},"page":"188-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ocular Surface Ion Transport and Dry Eye Disease"],"prefix":"10.1007","volume":"10","author":[{"given":"Ethan S.","family":"Lindgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Cil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Verkman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2327-5221","authenticated-orcid":false,"given":"Neel D.","family":"Pasricha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,20]]},"reference":[{"issue":"1","key":"295_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.preteyeres.2011.10.001","volume":"31","author":"M Zhao","year":"2012","unstructured":"Zhao M, Chalmers L, Cao L, Vieira AC, Mannis M, Reid B. Electrical signaling in control of ocular cell behaviors. Prog Retin Eye Res. 2012;31(1):65\u201388.","journal-title":"Prog Retin Eye Res."},{"key":"295_CR2","doi-asserted-by":"crossref","unstructured":"Devor DC, Hamilton KL. Ion channels and transporters of epithelia in health and disease. New York, Imprint: Springer; 2016.","DOI":"10.1007\/978-1-4939-3366-2"},{"issue":"10290","key":"295_CR3","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","volume":"397","author":"M Shteinberg","year":"2021","unstructured":"Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195\u2013211.","journal-title":"Lancet."},{"issue":"4 Pt 1","key":"295_CR4","first-page":"865","volume":"8","author":"M Mrugacz","year":"2004","unstructured":"Mrugacz M, Minorowska A, Bakunowicz-Lazarczyk A, Zywalewska N. Dry eye syndrome in children with cystic fibrosis. Med Wieku Rozwoj. 2004;8(4 Pt 1):865\u201370.","journal-title":"Med Wieku Rozwoj."},{"issue":"2","key":"295_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1096\/fj.201600891R","volume":"31","author":"O Cil","year":"2017","unstructured":"Cil O, Phuan PW, Gillespie AM, Lee S, Tradtrantip L, Yin J, et al. Benzopyrimido-pyrrolo-oxazine-dione CFTR inhibitor (R)-BPO-27 for antisecretory therapy of diarrheas caused by bacterial enterotoxins. FASEB J. 2017;31(2):751\u201360.","journal-title":"FASEB J."},{"issue":"1","key":"295_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1167\/iovs.05-1082","volume":"47","author":"MH Levin","year":"2006","unstructured":"Levin MH, Kim JK, Hu J, Verkman AS. Potential difference measurements of ocular surface na+ absorption analyzed using an electrokinetic model. Invest Ophthalmol Vis Sci. 2006;47(1):306\u201316.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"11","key":"295_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1167\/tvst.9.11.20","volume":"9","author":"ND Pasricha","year":"2020","unstructured":"\u2022\u2022 Pasricha ND, Smith AJ, Levin MH, Schallhorn JM, Verkman AS. Ocular surface potential difference measured in human subjects to study ocular surface ion transport. Transl Vis Sci Technol. 2020;9(11):20 A human clinical pilot study describing the experimental procedure of human OSPD and demonstrating safety and reliability of OSPD measurements in healthy controls and CF patients.","journal-title":"Transl Vis Sci Technol"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"830853","DOI":"10.3389\/fmed.2022.830853","volume":"9","author":"S Yang","year":"2022","unstructured":"\u2022\u2022 Yang S, Wu Y, Wang C, Jin X. Ocular surface ion-channels are closely related to dry eye: key research focus on innovative drugs for dry eye. Front Med (Lausanne). 2022;9:830853 A review of various ion transporters on the ocular surface and the clinical and basic research results of ion channel regulatory compounds related to DED.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"295_CR9","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtos.2017.08.003","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802\u201312.","journal-title":"Ocul Surf."},{"issue":"3","key":"295_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","volume":"15","author":"F Stapleton","year":"2017","unstructured":"Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334\u201365.","journal-title":"Ocul Surf."},{"issue":"6 Suppl","key":"295_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1590\/S0004-27492008000700017","volume":"71","author":"CS de Paiva","year":"2008","unstructured":"de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. Arq Bras Oftalmol. 2008;71(6 Suppl):89\u201395.","journal-title":"Arq Bras Oftalmol."},{"issue":"8","key":"295_CR12","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/15287394.2020.1867274","volume":"84","author":"JD Lee","year":"2021","unstructured":"Lee JD, Kim HY, Park JJ, Oh SB, Goo H, Cho KJ, et al. Metabolomics approach to biomarkers of dry eye disease using (1)H-NMR in rats. J Toxicol Environ Health A. 2021;84(8):313\u201330.","journal-title":"J Toxicol Environ Health A."},{"key":"295_CR13","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/OPTH.S126668","volume":"12","author":"IV Lollett","year":"2018","unstructured":"Lollett IV, Galor A. Dry eye syndrome: developments and lifitegrast in perspective. Clin Ophthalmol. 2018;12:125\u201339.","journal-title":"Clin Ophthalmol."},{"issue":"2","key":"295_CR14","first-page":"464","volume":"296","author":"L Al-Nakkash","year":"2001","unstructured":"Al-Nakkash L, Hu S, Li M, Hwang TC. A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J Pharmacol Exp Ther. 2001;296(2):464\u201372.","journal-title":"J Pharmacol Exp Ther."},{"issue":"7","key":"295_CR15","doi-asserted-by":"publisher","first-page":"C767","DOI":"10.1152\/ajpcell.00195.2012","volume":"303","author":"D Yu","year":"2012","unstructured":"Yu D, Thelin WR, Rogers TD, Stutts MJ, Randell SH, Grubb BR, et al. Regional differences in rat conjunctival ion transport activities. Am J Physiol Cell Physiol. 2012;303(7):C767\u201380.","journal-title":"Am J Physiol Cell Physiol."},{"issue":"2","key":"295_CR16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00232-005-0849-1","volume":"210","author":"MH Levin","year":"2006","unstructured":"Levin MH, Verkman AS. Aquaporins and CFTR in ocular epithelial fluid transport. J Membr Biol. 2006;210(2):105\u201315.","journal-title":"J Membr Biol."},{"issue":"3","key":"295_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1076\/ceyr.24.3.182.8297","volume":"24","author":"HC Turner","year":"2002","unstructured":"Turner HC, Bernstein A, Candia OA. Presence of CFTR in the conjunctival epithelium. Curr Eye Res. 2002;24(3):182\u20137.","journal-title":"Curr Eye Res."},{"issue":"6","key":"295_CR18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.exer.2010.03.013","volume":"90","author":"L Cao","year":"2010","unstructured":"Cao L, Zhang XD, Liu X, Chen TY, Zhao M. Chloride channels and transporters in human corneal epithelium. Exp Eye Res. 2010;90(6):771\u20139.","journal-title":"Exp Eye Res."},{"issue":"1","key":"295_CR19","doi-asserted-by":"publisher","first-page":"C79","DOI":"10.1152\/ajpcell.00296.2014","volume":"308","author":"H Xu","year":"2015","unstructured":"Xu H, Zhao Y, Li J, Wang M, Lian F, Gao M, et al. Loss of NHE8 expression impairs ocular surface function in mice. Am J Physiol Cell Physiol. 2015;308(1):C79\u201387.","journal-title":"Am J Physiol Cell Physiol."},{"key":"295_CR20","doi-asserted-by":"crossref","unstructured":"Oak AA, Chu T, Yottasan P, Chhetri PD, Zhu J, Du Bois J, et al. Lubiprostone is non-selective activator of cAMP-gated ion channels and Clc-2 has a minor role in its prosecretory effect in intestinal epithelial cells. Mol Pharmacol. 2022.","DOI":"10.1016\/S0016-5085(22)61668-8"},{"issue":"2","key":"295_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.jtos.2019.01.007","volume":"17","author":"J Almassy","year":"2019","unstructured":"Almassy J, Diszhazi G, Skaliczki M, Marton I, Magyar ZE, Nanasi PP, et al. Expression of BK channels and Na(+)-K(+) pumps in the apical membrane of lacrimal acinar cells suggests a new molecular mechanism for primary tear-secretion. Ocul Surf. 2019;17(2):272\u20137.","journal-title":"Ocul Surf."},{"issue":"3","key":"295_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/jop.2019.0087","volume":"36","author":"X Chen","year":"2020","unstructured":"\u2022 Chen X, Lee S, Zhang T, Duan T, Pasricha ND, Schallhorn JM, et al. Nanomolar potency aminophenyltriazine cftr activator reverses corneal epithelial injury in a mouse model of dry eye. J Ocul Pharmacol Ther. 2020;36(3):147\u201353 An original study demonstrating the efficacy of CFTRact-K089 (now known as VSJ-110), a nanomolar potent CFTR activator, in reversing corneal epithelial damage in a lacrimal duct cautery aqueous-deficient mouse model of DED.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"295_CR23","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1096\/fj.201500180","volume":"30","author":"AM Flores","year":"2016","unstructured":"Flores AM, Casey SD, Felix CM, Phuan PW, Verkman AS, Levin MH. Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease. FASEB J. 2016;30(5):1789\u201397.","journal-title":"FASEB J."},{"issue":"11","key":"295_CR24","doi-asserted-by":"publisher","first-page":"4506","DOI":"10.1167\/iovs.17-22525","volume":"58","author":"CM Felix","year":"2017","unstructured":"Felix CM, Lee S, Levin MH, Verkman AS. Pro-secretory activity and pharmacology in rabbits of an aminophenyl-1,3,5-Triazine CFTR activator for dry eye disorders. Invest Ophthalmol Vis Sci. 2017;58(11):4506\u201313.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"295_CR25","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1021\/acs.jmedchem.6b01792","volume":"60","author":"S Lee","year":"2017","unstructured":"Lee S, Phuan PW, Felix CM, Tan JA, Levin MH, Verkman AS. Nanomolar-potency aminophenyl-1,3,5-triazine activators of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel for prosecretory therapy of dry eye diseases. J Med Chem. 2017;60(3):1210\u20138.","journal-title":"J Med Chem."},{"issue":"6","key":"295_CR26","doi-asserted-by":"publisher","first-page":"C932","DOI":"10.1152\/ajpcell.00334.2021","volume":"321","author":"AS Verkman","year":"2021","unstructured":"Verkman AS, Galietta LJV. Chloride transport modulators as drug candidates. Am J Physiol Cell Physiol. 2021;321(6):C932\u2013C46.","journal-title":"Am J Physiol Cell Physiol."},{"issue":"2","key":"295_CR27","doi-asserted-by":"publisher","first-page":"C595","DOI":"10.1152\/ajpcell.2001.281.2.C595","volume":"281","author":"Y Li","year":"2001","unstructured":"Li Y, Kuang K, Yerxa B, Wen Q, Rosskothen H, Fischbarg J. Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion. Am J Physiol Cell Physiol. 2001;281(2):C595\u2013602.","journal-title":"Am J Physiol Cell Physiol."},{"issue":"2","key":"295_CR28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000076887","volume":"36","author":"T Murakami","year":"2004","unstructured":"Murakami T, Fujihara T, Horibe Y, Nakamura M. Diquafosol elicits increases in net Cl- transport through P2Y2 receptor stimulation in rabbit conjunctiva. Ophthalmic Res. 2004;36(2):89\u201393.","journal-title":"Ophthalmic Res."},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.exer.2015.10.013","volume":"143","author":"YS Byun","year":"2016","unstructured":"Byun YS, Yoo YS, Kwon JY, Joo JS, Lim SA, Whang WJ, et al. Diquafosol promotes corneal epithelial healing via intracellular calcium-mediated ERK activation. Exp Eye Res. 2016;143:89\u201397.","journal-title":"Exp Eye Res."},{"key":"295_CR30","unstructured":"Order Instituting Cease and Desist Proceedings, Making Findings, and Imposing Cease-And-Desist Order Pursuant to Section 21C of the Securities Exchange Act of 1934, In the Matter of Inspire Pharmaceuticals, Inc., et al., Admin. Proceeding File No. 3-13264 (Securities and Exhange Comm\u2019n Sep. 30, 2008). 2008. [Available from: https:\/\/www.sec.gov\/litigation\/admin\/2008\/34-58690.pdf."},{"issue":"15","key":"295_CR31","first-page":"957","volume":"54","author":"J Boyer","year":"2013","unstructured":"Boyer J, Johnson MR, Ansede J, Donn K, Boucher R, Thelin W. P-321, a novel long-acting epithelial sodium channel (ENaC) blocker for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2013;54(15):957.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"295_CR32","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/jop.2011.0157","volume":"28","author":"WR Thelin","year":"2012","unstructured":"Thelin WR, Johnson MR, Hirsh AJ, Kublin CL, Zoukhri D. Effect of topically applied epithelial sodium channel inhibitors on tear production in normal mice and in mice with induced aqueous tear deficiency. J Ocul Pharmacol Ther. 2012;28(4):433\u20138.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"10","key":"295_CR33","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.18240\/ijo.2021.10.07","volume":"14","author":"Y Eom","year":"2021","unstructured":"Eom Y, Kim HM. Clinical effectiveness of diquafosol ophthalmic solution 3% in Korean patients with dry eye disease: a multicenter prospective observational study. Int J Ophthalmol. 2021;14(10):1518\u201326.","journal-title":"Int J Ophthalmol."},{"issue":"8","key":"295_CR34","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.1007\/s12325-022-02194-2","volume":"39","author":"Y Hori","year":"2022","unstructured":"\u2022 Hori Y, Oka K, Inai M. Efficacy and safety of the long-acting diquafosol ophthalmic solution DE-089C in patients with dry eye: a randomized, double-masked, placebo-controlled phase 3 study. Adv Ther. 2022;39(8):3654\u201367 A randomized clinical trial in Japan demonstrating safety and efficacy of DE-089C, a long-acting diquafosol ophthalmic solution, compared to placebo in reducing fluorescein corneal and LG conjunctival staining over a 4-week period.","journal-title":"Adv Ther"},{"key":"295_CR35","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Huang R, Su C, Fang L, Lu J, Chen J, Ding Y. Dry eye syndrome: comprehensive etiologies and recent clinical trials. Int Ophthalmol. 2022; A review outlining the etiologies of DED and upcoming and ongoing clinical trials for DED therapies.","DOI":"10.1007\/s10792-022-02320-7"},{"issue":"1","key":"295_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052488","volume":"12","author":"M Miura","year":"2022","unstructured":"Miura M, Inomata T, Nojiri S, Sung J, Nagao M, Shimazaki J, et al. Clinical efficacy of diquafosol sodium 3% versus hyaluronic acid 0.1% in patients with dry eye disease after cataract surgery: a protocol for a single-centre, randomised controlled trial. BMJ Open. 2022;12(1):e052488.","journal-title":"BMJ Open."},{"issue":"1","key":"295_CR37","doi-asserted-by":"publisher","first-page":"9124","DOI":"10.1038\/s41598-021-88589-7","volume":"11","author":"S Kim","year":"2021","unstructured":"Kim S, Shin J, Lee JE. A randomised, prospective study of the effects of 3% diquafosol on ocular surface following cataract surgery. Sci Rep. 2021;11(1):9124.","journal-title":"Sci Rep."},{"issue":"4","key":"295_CR38","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/15569527.2021.1973022","volume":"40","author":"L Li","year":"2021","unstructured":"Li L, Jin R, Li Y, Yoon HS, Yoon HJ, Yoon KC. Effects of eye drops containing a mixture of 3% diquafosol sodium and tocopherol acetate (vitamin E) on the ocular surface of murine dry eye. Cutan Ocul Toxicol. 2021;40(4):350\u20138.","journal-title":"Cutan Ocul Toxicol."},{"issue":"11","key":"295_CR39","doi-asserted-by":"publisher","first-page":"5534","DOI":"10.1007\/s12325-021-01910-8","volume":"38","author":"T Ogami","year":"2021","unstructured":"Ogami T, Asano H, Hiraoka T, Yamada Y, Oshika T. The effect of diquafosol ophthalmic solution on clinical parameters and visual function in soft contact lens-related dry eye. Adv Ther. 2021;38(11):5534\u201347.","journal-title":"Adv Ther."},{"issue":"2","key":"295_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1089\/jop.2021.0083","volume":"38","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Zhang H, Qin G, Wu Y, Song Y, Yang L, et al. Impact of diquafosol ophthalmic solution on tear film and dry eye symptom in type 2 diabetic dry eye: a pilot study. J Ocul Pharmacol Ther. 2022;38(2):133\u201340.","journal-title":"J Ocul Pharmacol Ther."},{"key":"295_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.2147\/OPTH.S242764","volume":"14","author":"A Dota","year":"2020","unstructured":"Dota A, Sakamoto A, Nagano T, Murakami T, Matsugi T. Effect of diquafosol ophthalmic solution on airflow-induced ocular surface disorder in diabetic rats. Clin Ophthalmol. 2020;14:1019\u201324.","journal-title":"Clin Ophthalmol."},{"key":"295_CR42","doi-asserted-by":"crossref","unstructured":"Yagi-Yaguchi Y, Kojima T, Higa K, Dogru M, Ibrahim OM, Shimizu T, et al. The effects of 3% diquafosol sodium eye drops on tear function and the ocular surface of Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice treated with antiglaucoma eye medications. Diagnostics (Basel). 2020;10(1).","DOI":"10.3390\/diagnostics10010020"},{"issue":"2","key":"295_CR43","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s12325-019-01188-x","volume":"37","author":"Y Ohashi","year":"2020","unstructured":"Ohashi Y, Munesue M, Shimazaki J, Takamura E, Yokoi N, Watanabe H, et al. Long-term safety and effectiveness of diquafosol for the treatment of dry eye in a real-world setting: a prospective observational study. Adv Ther. 2020;37(2):707\u201317.","journal-title":"Adv Ther."},{"issue":"15","key":"295_CR44","doi-asserted-by":"publisher","first-page":"5035","DOI":"10.1167\/iovs.19-27872","volume":"60","author":"YW Ji","year":"2019","unstructured":"Ji YW, Kim HM, Ryu SY, Oh JW, Yeo A, Choi CY, et al. Changes in human tear proteome following topical treatment of dry eye disease: cyclosporine a versus diquafosol tetrasodium. Invest Ophthalmol Vis Sci. 2019;60(15):5035\u201344.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"10","key":"295_CR45","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.18240\/ijo.2019.10.06","volume":"12","author":"DH Kang","year":"2019","unstructured":"Kang DH, Lee YW, Hwang KY, Koh KM, Kwon YA, Kim BY, et al. Changes of tear film lipid layer thickness by 3% diquafosol ophthalmic solutions in patients with dry eye syndrome. Int J Ophthalmol. 2019;12(10):1555\u201360.","journal-title":"Int J Ophthalmol."},{"issue":"1","key":"295_CR46","doi-asserted-by":"publisher","first-page":"12659","DOI":"10.1038\/s41598-019-49159-0","volume":"9","author":"I Jun","year":"2019","unstructured":"Jun I, Choi S, Lee GY, Choi YJ, Lee HK, Kim EK, et al. Effects of preservative-free 3% diquafosol in patients with pre-existing dry eye disease after cataract surgery: a randomized clinical trial. Sci Rep. 2019;9(1):12659.","journal-title":"Sci Rep."},{"issue":"1","key":"295_CR47","doi-asserted-by":"publisher","first-page":"9091","DOI":"10.1038\/s41598-019-45475-7","volume":"9","author":"S Fukuoka","year":"2019","unstructured":"Fukuoka S, Arita R. Tear film lipid layer increase after diquafosol instillation in dry eye patients with meibomian gland dysfunction: a randomized clinical study. Sci Rep. 2019;9(1):9091.","journal-title":"Sci Rep."},{"issue":"4","key":"295_CR48","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000492896","volume":"61","author":"K Nam","year":"2019","unstructured":"Nam K, Kim HJ, Yoo A. Efficacy and safety of topical 3% diquafosol ophthalmic solution for the treatment of multifactorial dry eye disease: meta-analysis of randomized clinical trials. Ophthalmic Res. 2019;61(4):188\u201398.","journal-title":"Ophthalmic Res."},{"issue":"1","key":"295_CR49","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12886-019-1136-8","volume":"19","author":"CH Park","year":"2019","unstructured":"Park CH, Lee HK, Kim MK, Kim EC, Kim JY, Kim TI, et al. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial. BMC Ophthalmol. 2019;19(1):131.","journal-title":"BMC Ophthalmol."},{"issue":"14","key":"295_CR50","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.1167\/iovs.16-20303","volume":"57","author":"JM Benitez-Del-Castillo","year":"2016","unstructured":"Benitez-Del-Castillo JM, Moreno-Montanes J, Jimenez-Alfaro I, Munoz-Negrete FJ, Turman K, Palumaa K, et al. Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease. Invest Ophthalmol Vis Sci. 2016;57(14):6447\u201354.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"4","key":"295_CR51","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/13543784.2018.1457647","volume":"27","author":"J Moreno-Montanes","year":"2018","unstructured":"Moreno-Montanes J, Bleau AM, Jimenez AI. Tivanisiran, a novel siRNA for the treatment of dry eye disease. Expert Opin Investig Drugs. 2018;27(4):421\u20136.","journal-title":"Expert Opin Investig Drugs."},{"issue":"9","key":"295_CR52","first-page":"305","volume":"60","author":"KS Crawford","year":"2019","unstructured":"Crawford KS, Schuh C, Schuh J, Hsu H. Effects of ALY688 on atropine-induced dry eye in rabbits. Invest Ophthal Vis Sci. 2019;60(9):305.","journal-title":"Invest Ophthal Vis Sci."},{"issue":"19","key":"295_CR53","doi-asserted-by":"publisher","first-page":"8329","DOI":"10.18632\/aging.102322","volume":"11","author":"Y Shikama","year":"2019","unstructured":"Shikama Y, Kurosawa M, Furukawa M, Ishimaru N, Matsushita K. Involvement of adiponectin in age-related increases in tear production in mice. Aging (Albany NY). 2019;11(19):8329\u201346.","journal-title":"Aging (Albany NY)."},{"issue":"1","key":"295_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1167\/iovs.12-10648","volume":"54","author":"Z Li","year":"2013","unstructured":"Li Z, Woo JM, Chung SW, Kwon MY, Choi JS, Oh HJ, et al. Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye. Invest Ophthalmol Vis Sci. 2013;54(1):155\u201362.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"1","key":"295_CR55","doi-asserted-by":"publisher","first-page":"10500","DOI":"10.1038\/s41598-018-28861-5","volume":"8","author":"CE Kim","year":"2018","unstructured":"Kim CE, Kleinman HK, Sosne G, Ousler GW, Kim K, Kang S, et al. RGN-259 (thymosin beta4) improves clinically important dry eye efficacies in comparison with prescription drugs in a dry eye model. Sci Rep. 2018;8(1):10500.","journal-title":"Sci Rep."},{"issue":"5","key":"295_CR56","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/ICO.0000000000000379","volume":"34","author":"G Sosne","year":"2015","unstructured":"Sosne G, Dunn SP, Kim C. Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea. 2015;34(5):491\u20136.","journal-title":"Cornea."},{"key":"295_CR57","first-page":"877","volume":"9","author":"G Sosne","year":"2015","unstructured":"Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model. Clin Ophthalmol. 2015;9:877\u201384.","journal-title":"Clin Ophthalmol."},{"key":"295_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2147\/JEP.S237487","volume":"13","author":"M Baiula","year":"2021","unstructured":"\u2022 Baiula M, Spampinato S. Experimental pharmacotherapy for dry eye disease: a review. J Exp Pharmacol. 2021;13:345\u201358 A review that details novel approaches to the treatment of DED currently in preclinical and clinical development.","journal-title":"J Exp Pharmacol"},{"issue":"7","key":"295_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158868","volume":"11","author":"GL Chen","year":"2016","unstructured":"Chen GL, Lei M, Zhou LP, Zeng B, Zou F. Borneol is a TRPM8 agonist that increases ocular surface wetness. PLoS One. 2016;11(7):e0158868.","journal-title":"PLoS One."},{"issue":"9","key":"295_CR60","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1089\/jop.2017.0050","volume":"33","author":"P Corcoran","year":"2017","unstructured":"Corcoran P, Hollander DA, Ousler GW 3rd, Angjeli E, Rimmer D, Lane K, et al. Dynamic sensitivity of corneal TRPM8 receptors to menthol instillation in dry eye versus normal subjects. J Ocul Pharmacol Ther. 2017;33(9):686\u201392.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"1","key":"295_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12886-017-0495-2","volume":"17","author":"JM Yang","year":"2017","unstructured":"Yang JM, Li F, Liu Q, Ruedi M, Wei ET, Lentsman M, et al. A novel TRPM8 agonist relieves dry eye discomfort. BMC Ophthalmol. 2017;17(1):101.","journal-title":"BMC Ophthalmol."},{"key":"295_CR62","doi-asserted-by":"crossref","unstructured":"Yang JM, Wei ET, Kim SJ, Yoon KC. TRPM8 channels and dry eye. Pharmaceuticals (Basel). 2018;11(4).","DOI":"10.3390\/ph11040125"},{"key":"295_CR63","doi-asserted-by":"crossref","unstructured":"\u2022 Yoon HJ, Kim J, Yang JM, Wei ET, Kim SJ, Yoon KC. Topical TRPM8 agonist for relieving neuropathic ocular pain in patients with dry eye: A pilot study. J Clin Med. 2021;10(2) A human clinical pilot study demonstrating the efficacy of C3, a TRPM8 agonist, on relieving neuropathic ocular pain in DED patients.","DOI":"10.3390\/jcm10020250"},{"key":"295_CR64","doi-asserted-by":"crossref","unstructured":"\u2022 Jeon D, Jun I, Lee HK, Park J, Kim BR, Ryu K, et al. Novel CFTR activator Cact-3 ameliorates ocular surface dysfunctions in scopolamine-induced dry eye mice. Int J Mol Sci. 2022;23(9) An original study using high-throughput screening of small molecules for CFTR activation and demonstrating robust activity of Cact-3, a novel CFTR activator.","DOI":"10.3390\/ijms23095206"},{"key":"295_CR65","doi-asserted-by":"crossref","unstructured":"\u2022 Lee HK, Park J, Kim BR, Jun I, Kim TI, Namkung W. Isorhamnetin ameliorates dry eye disease via cftr activation in mice. Int J Mol Sci. 2021;22(8) An original study using high-throughput screening of natural products for CFTR activation and demonstrating robust activity of isorhamnetin, a novel CFTR activator.","DOI":"10.3390\/ijms22083954"},{"key":"295_CR66","doi-asserted-by":"publisher","first-page":"12034","DOI":"10.1038\/ncomms12034","volume":"7","author":"T Nakamachi","year":"2016","unstructured":"Nakamachi T, Ohtaki H, Seki T, Yofu S, Kagami N, Hashimoto H, et al. PACAP suppresses dry eye signs by stimulating tear secretion. Nat Commun. 2016;7:12034.","journal-title":"Nat Commun."},{"key":"295_CR67","doi-asserted-by":"crossref","unstructured":"\u2022 Hirabayashi T, Shibato J, Kimura A, Yamashita M, Takenoya F, Shioda S. Potential therapeutic role of pituitary adenylate cyclase-activating polypeptide for dry eye disease. Int J Mol Sci. 2022;23(2) A review of causes and symptoms of DED that includes an overview of PACAP as a therapeutic candidate for DED.","DOI":"10.3390\/ijms23020664"},{"issue":"8","key":"295_CR68","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1167\/iovs.15-17088","volume":"56","author":"Y Ma","year":"2015","unstructured":"Ma Y, Zhao S, Wang X, Shen S, Ma M, Xu W, et al. A new recombinant PACAP-derived peptide efficiently promotes corneal wound repairing and lacrimal secretion. Invest Ophthalmol Vis Sci. 2015;56(8):4336\u201349.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"6","key":"295_CR69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1254\/fpj.151.232","volume":"151","author":"T Nakamachi","year":"2018","unstructured":"Nakamachi T. Novel tear secretion system - the effect and the mechanism of PACAP on tear secretion. Nihon Yakurigaku Zasshi. 2018;151(6):232\u20138.","journal-title":"Nihon Yakurigaku Zasshi."},{"issue":"3","key":"295_CR70","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12031-018-1087-1","volume":"68","author":"S Shioda","year":"2019","unstructured":"Shioda S, Takenoya F, Hirabayashi T, Wada N, Seki T, Nonaka N, et al. Effects of PACAP on dry eye symptoms, and possible use for therapeutic application. J Mol Neurosci. 2019;68(3):420\u20136.","journal-title":"J Mol Neurosci."},{"issue":"3","key":"295_CR71","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1097\/01.j.pain.0000460335.49525.17","volume":"156","author":"G Callejo","year":"2015","unstructured":"Callejo G, Castellanos A, Castany M, Gual A, Luna C, Acosta MC, et al. Acid-sensing ion channels detect moderate acidifications to induce ocular pain. Pain. 2015;156(3):483\u201395.","journal-title":"Pain."},{"issue":"4","key":"295_CR72","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1167\/iovs.04-1314","volume":"46","author":"MH Levin","year":"2005","unstructured":"Levin MH, Verkman AS. CFTR-regulated chloride transport at the ocular surface in living mice measured by potential differences. Invest Ophthalmol Vis Sci. 2005;46(4):1428\u201334.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"Suppl 2","key":"295_CR73","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jcf.2004.05.026","volume":"3","author":"H Li","year":"2004","unstructured":"Li H, Sheppard DN, Hug MJ. Transepithelial electrical measurements with the Ussing chamber. J Cyst Fibros. 2004;3(Suppl 2):123\u20136.","journal-title":"J Cyst Fibros."},{"issue":"2 Pt 1","key":"295_CR74","doi-asserted-by":"publisher","first-page":"C215","DOI":"10.1152\/ajpcell.1990.259.2.C215","volume":"259","author":"OA Candia","year":"1990","unstructured":"Candia OA. Forskolin-induced HCO3- current across apical membrane of the frog corneal epithelium. Am J Physiol. 1990;259(2 Pt 1):C215\u201323.","journal-title":"Am J Physiol."},{"issue":"4","key":"295_CR75","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3109\/02713688509025146","volume":"4","author":"OA Candia","year":"1985","unstructured":"Candia OA. The flux ratio of the Na-Cl cotransport mechanism in the frog corneal epithelium. Curr Eye Res. 1985;4(4):333\u20138.","journal-title":"Curr Eye Res."},{"key":"295_CR76","doi-asserted-by":"crossref","unstructured":"Segev A, Garcia-Oscos F, Kourrich S. Whole-cell patch-clamp recordings in brain slices. J Vis Exp. 2016;112.","DOI":"10.3791\/54024"},{"key":"295_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3389\/fnsyn.2019.00015","volume":"11","author":"JS Jouhanneau","year":"2019","unstructured":"Jouhanneau JS, Poulet JFA. Multiple two-photon targeted whole-cell patch-clamp recordings from monosynaptically connected neurons in vivo. Front Synaptic Neurosci. 2019;11:15.","journal-title":"Front Synaptic Neurosci."},{"key":"295_CR78","doi-asserted-by":"crossref","unstructured":"Oak AA, Chhetri PD, Rivera AA, Verkman AS, Cil O. Repurposing calcium-sensing receptor agonist cinacalcet for treatment of CFTR-mediated secretory diarrheas. JCI. Insight. 2021;6(4).","DOI":"10.1172\/jci.insight.146823"},{"key":"295_CR79","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/978-1-4939-8935-5_25","volume":"1897","author":"S Magaki","year":"2019","unstructured":"Magaki S, Hojat SA, Wei B, So A, Yong WH. An Introduction to the Performance of Immunohistochemistry. Methods Mol Biol. 2019;1897:289\u201398.","journal-title":"Methods Mol Biol."},{"issue":"10","key":"295_CR80","doi-asserted-by":"publisher","first-page":"4309","DOI":"10.1167\/iovs.05-1504","volume":"47","author":"A Tomlinson","year":"2006","unstructured":"Tomlinson A, Khanal S, Ramaesh K, Diaper C, McFadyen A. Tear film osmolarity: determination of a referent for dry eye diagnosis. Invest Ophthalmol Vis Sci. 2006;47(10):4309\u201315.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"9","key":"295_CR81","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/ICO.0b013e3181cd9a1d","volume":"29","author":"A Tomlinson","year":"2010","unstructured":"Tomlinson A, McCann LC, Pearce EI. Comparison of human tear film osmolarity measured by electrical impedance and freezing point depression techniques. Cornea. 2010;29(9):1036\u201341.","journal-title":"Cornea."},{"issue":"12","key":"295_CR82","doi-asserted-by":"publisher","first-page":"6125","DOI":"10.1167\/iovs.10-5390","volume":"51","author":"BD Sullivan","year":"2010","unstructured":"Sullivan BD, Whitmer D, Nichols KK, Tomlinson A, Foulks GN, Geerling G, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci. 2010;51(12):6125\u201330.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"7","key":"295_CR83","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3109\/02713683.2010.484557","volume":"35","author":"P Versura","year":"2010","unstructured":"Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res. 2010;35(7):553\u201364.","journal-title":"Curr Eye Res."},{"key":"295_CR84","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/B978-0-7020-7168-3.00005-2","volume-title":"Contact lenses","author":"JP Craig","year":"2019","unstructured":"Craig JP, Downie LE. 5 - tears and contact lenses. In: Phillips AJ, Speedwell L, editors. Contact lenses. Sixth ed. London: Elsevier; 2019. p. 97\u2013116.","edition":"Sixth Edition"},{"key":"295_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/B978-0-323-82753-9.00002-3","volume-title":"Dry eye disease","author":"KK Nichols","year":"2023","unstructured":"\u2022\u2022 Nichols KK, Mousavi M. Chapter 2 - clinical assessments of dry eye disease: tear film and ocular surface health. In: Galor A, editor. Dry eye disease: Elsevier; 2023. p. 15\u201323. A textbook chapter detailing various techniques used to diagnose DED and clinically assess the health of the ocular surface."},{"issue":"6","key":"295_CR86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1167\/tvst.8.6.34","volume":"8","author":"M Pellegrini","year":"2019","unstructured":"Pellegrini M, Bernabei F, Moscardelli F, Vagge A, Scotto R, Bovone C, et al. Assessment of corneal fluorescein staining in different dry eye subtypes using digital image analysis. Transl Vis Sci Technol. 2019;8(6):34.","journal-title":"Transl Vis Sci Technol."},{"issue":"5","key":"295_CR87","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1167\/iovs.08-3033","volume":"50","author":"J Ruiz-Ederra","year":"2009","unstructured":"Ruiz-Ederra J, Levin MH, Verkman AS. In situ fluorescence measurement of tear film [Na+], [K+], [Cl-], and pH in mice shows marked hypertonicity in aquaporin-5 deficiency. Invest Ophthalmol Vis Sci. 2009;50(5):2132\u20138.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"295_CR88","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.preteyeres.2008.04.001","volume":"27","author":"AS Verkman","year":"2008","unstructured":"Verkman AS, Ruiz-Ederra J, Levin M. Functions of aquaporins in the eye. Progress in retinal and eye research. 2008;27:420\u201333.","journal-title":"Progress in retinal and eye research."},{"issue":"2","key":"295_CR89","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jobcr.2020.12.001","volume":"11","author":"G Abughanam","year":"2021","unstructured":"Abughanam G, Maria OM, Tran SD. Studying Sjogren's syndrome in mice: What is the best available model? J Oral Biol Craniofac Res. 2021;11(2):245\u201355.","journal-title":"J Oral Biol Craniofac Res."},{"issue":"3","key":"295_CR90","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.2353\/ajpath.2009.081058","volume":"175","author":"B Turpie","year":"2009","unstructured":"Turpie B, Yoshimura T, Gulati A, Rios JD, Dartt DA, Masli S. Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am J Pathol. 2009;175(3):1136\u201347.","journal-title":"Am J Pathol."},{"issue":"8","key":"295_CR91","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3109\/02713683.2013.877936","volume":"39","author":"S Masli","year":"2014","unstructured":"Masli S, Sheibani N, Cursiefen C, Zieske J. Matricellular protein thrombospondins: influence on ocular angiogenesis, wound healing and immuneregulation. Curr Eye Res. 2014;39(8):759\u201374.","journal-title":"Curr Eye Res."},{"issue":"5","key":"295_CR92","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1172\/JCI1684","volume":"101","author":"J Lawler","year":"1998","unstructured":"Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, et al. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest. 1998;101(5):982\u201392.","journal-title":"J Clin Invest."},{"issue":"1","key":"295_CR93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00005-009-0002-4","volume":"57","author":"BH Lee","year":"2009","unstructured":"Lee BH, Tudares MA, Nguyen CQ. Sjogren's syndrome: an old tale with a new twist. Arch Immunol Ther Exp (Warsz). 2009;57(1):57\u201366.","journal-title":"Arch Immunol Ther Exp (Warsz)."}],"container-title":["Current Ophthalmology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40135-022-00295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40135-022-00295-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40135-022-00295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T05:46:29Z","timestamp":1670391989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40135-022-00295-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,20]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1007\/s40135-022-00295-3","relation":{},"ISSN":["2167-4868"],"issn-type":[{"value":"2167-4868","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,20]]},"assertion":[{"value":"31 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.D.P. and A.S.V. are named inventors on patent applications on ocular surface potential difference measurements owned by the University of California San Francisco. O.C. and A.S.V. are named inventors on patent applications on CFTR activators for dry eye disease and other indications, owned by the University of California San Francisco and licensed to Vanda Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}